Quantitative multimodality imaging in cancer research and therapy

Nature Reviews Clinical Oncology

Volumn 11, Issue 11, 2014, Pages 670-680

  Yankeelov, Thomas E ^a   Abramson, Richard G ^a   Quarles, C Chad ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; DEOXYHEMOGLOBIN; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROESTRADIOL F 18; RADIOPHARMACEUTICAL AGENT; THYMIDINE KINASE 1; THYMIDINE PHOSPHATE; UNCLASSIFIED DRUG;

APPARENT DIFFUSION COEFFICIENT; BOLD SIGNAL; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOARCHITECTURE; DIAGNOSTIC IMAGING; DRUG METABOLISM; ECHOGRAPHY; ENZYME ACTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENOMICS; GLUCOSE METABOLISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMODYNAMICS; HUMAN; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; OXYGEN CONSUMPTION; PATIENT MONITORING; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; RADIOTHERAPY PLANNING SYSTEM; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR VASCULARIZATION; VASODILATATION; COMPUTER ASSISTED TOMOGRAPHY; IMAGE PROCESSING; MEDICAL RESEARCH; MULTIMODAL IMAGING; NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; TRANSLATIONAL RESEARCH; TRENDS;

BIOMEDICAL RESEARCH; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MULTIMODAL IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84908502300     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.134     Document Type: Review

References (79)

1. Pisano, E. D. et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N. Engl. J. Med. 353, 1773-1783 (2005).
2. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
3. Yankeelov, T. E. & Gore, J. C. Dynamic-contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples. Curr. Med. Imaging Rev. 3, 91-107 (2009).
4. Ingrisch, M. & Sourbron, S. Tracer-kinetic modeling of dynamic contrast-enhanced MRI and CT: a primer. J. Pharmacokinet. Pharmacodyn. 40, 281-300 (2013).
5. Cosgrove, D. & Lassau, N. Imaging of perfusion using ultrasound. Eur. J. Nucl. Med. Mol. Imaging 37 (Suppl. 1), S65-S85 (2010).
6. Lewis, J. S. & Welch, M. J. PET imaging of hypoxia. Q. J. Nucl. Med. 45, 183-188 (2001).
7. Kurihara, H., Honda, N., Kono, Y. & Arai, Y. Radiolabelled agents for PET imaging of tumor hypoxia. Curr. Med. Chem. 19, 3282-3289 (2012).
8. Yankeelov, T. E., Pickens, D. R. & Price, R. R. (eds) Quantitative MRI of Cancer 193-202 (CRC Press, 2012) [Series Ed. Hendee, W. R. Imaging in Medical Diagnosis and Therapy].
9. He, X. & Yablonskiy, D. A. Quantitative BOLD: mapping of human cerebral deoxygenated blood volume and oxygen extraction fraction: default state. Magn. Reson. Med. 57, 115-126 (2007).
10. Anderson, A. W. et al. Effects of cell volume fraction changes on apparent diffusion in human cells. Magn. Reson. Imaging 18, 689-695 (2000).
11. Tehrani, O. S. & Shields, A. F. PET imaging of proliferation with pyrimidines. J. Nucl. Med. 54, 903-912 (2013).
12. Czernin, J. in PET: Molecular Imaging and its Biological Implications (ed. Phelps, M. E.) 321-388 (Springer, New York, 2004).
13. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
14. Sundararajan, L., Linden, H. M., Link, J. M., Krohn, K. A. & Mankoff, D. A. 18F-Fluoroestradiol. Semin. Nucl. Med. 37, 470-476 (2007).
15. Meng, Q. & Li, Z. Molecular imaging probes for diagnosis and therapy evaluation of breast cancer. Int. J. Biomed. Imaging 2013, 230487 (2013).
16. Treglia, G. et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann. Nucl. Med. 26, 451-461 (2012).
17. Kuhl, D. E., Hale, J. & Eaton, W. L. Transmission scanning: a useful adjunct to conventional emission scanning for accurately keying isotope deposition to radiographic anatomy. Radiology 87, 278-284 (1966).
18. Liew, S. C. & Hasegawa, B. H. Noise, resolution, and sensitivity considerations in the design of a single-slice emission-transmission computed tomographic system. Med. Phys. 18, 1002-1015 (1991).
19. Lang, T. F. et al. Description of a prototype emission-transmission computed tomography imaging system. J. Nucl. Med. 33, 1881-1887 (1992).
20. Kalki, K. et al. Myocardial perfusion imaging with a combined X-ray CT and SPECT system. J. Nucl. Med. 38, 1535-1540 (1997).
21. Beyer, T. et al. A combined PET/CT scanner for clinical oncology. J. Nucl. Med. 41, 1369-1379 (2000).
22. Kinahan, P. E., Townsend, D. W., Beyer, T. & Sashin, D. Attenuation correction for a combined 3D PET/CT scanner. Med. Phys. 25, 2046-2053 (1998).
23. Poeppel, T. D., Krause, B. J., Heusner, T. A., Boy, C., Bockisch, A. & Antoch, G. PET/CT for the staging and follow-up of patients with malignancies. Eur. J. Radiol. 70, 382-392 (2009).
24. Antoch, G. et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229, 526-533 (2003).
25. Lardinois, D. et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N. Engl. J. Med. 348, 2500-2507 (2003).
26. 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J. Nucl. Med. 44, 1797-1803 (2003).
27. Schöder, H., Yeung, H. W., Gonen, M., Kraus, D. & Larson, S. M. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 231, 65-72 (2004).
28. Pfannenberg, A. C. et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur. J. Nucl. Med. Mol. Imaging 30, 835-843 (2003).
29. Even-Sapir, E., Keidar, Z. & Bar-Shalom, R. Hybrid imaging (SPECT/CT and PET/CT)-improving the diagnostic accuracy of functional/metabolic and anatomic imaging. Semin. Nucl. Med. 39, 264-275 (2009).
30. Sauter, A. W., Wehrl, H. F., Kolb, A., Judenhofer, M. S. & Pichler, B. J. Combined PET/MRI: one step further in multimodality imaging. Trends Mol. Med. 16, 508-515 (2010).
31. Judenhofer, M. S. et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med. 14, 459-465 (2008).
32. Yankeelov, T. E. et al. Simultaneous PET-MRI in oncology: a solution looking for a problem? Magn. Reson. Imaging 30, 1342-1356 (2012).
33. Buchbender, C., Heusner, T. A., Lauenstein, T. C., Bockisch, A. & Antoch, G. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J. Nucl. Med. 53, 928-938 (2012).
34. Huang, S. H. et al. A comparative study of fused FDG PET/MRI, PET/CT, MRI, and CT imaging for assessing surrounding tissue invasion of advanced buccal squamous cell carcinoma. Clin. Nucl. Med. 36, 518-525 (2011).
35. 18F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT. Int. J. Clin. Oncol. 16, 408-415 (2011).
36. Catalano, O. A. et al. Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients-a hypothesis-generating exploratory study. Radiology 269, 857-869 (2013).
37. Borgwardt, L. et al. Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J. Clin. Oncol. 23, 3030-3037 (2005).
38. 18F-FDG PET/CT. Ann. Nucl. Med. 27, 554-563 (2013).
39. 18F-FDG PET/MRI for staging and restaging in paediatric oncology. Eur. J. Nucl. Med. Mol. Imaging 39, 1745-1755 (2012).
40. Walter, C. et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur. Radiol. 13, 1651-1656 (2003).
41. Zonari, P., Baraldi, P. & Crisi, G. Multimodal MRI in the characterization of glial neoplasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planar perfusion imaging. Neuroradiology 49, 795-803 (2007).
42. Yabuuchi, H. et al. Parotid gland tumors: can addition of diffusion-weighted MR imaging to dynamic contrast-enhanced MR imaging improve diagnostic accuracy in characterization? Radiology 249, 909-916 (2008).
43. 1H MR spectroscopic imaging-correlation with pathologic findings. Radiology 246, 480-484 (2008).
44. Segal, E. et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat. Biotechnol. 25, 675-680 (2007).
45. Gevaert, O. et al. Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data-methods and preliminary results. Radiology 264, 387-396 (2012).
46. Gutman, D. A. et al. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. 267, 560-569 (2013).
47. Zinn, P. O. et al. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS ONE 6, e25451 (2011).
48. Choi, H. Response evaluation of gastrointestinal stromal tumors. Oncologist 13 (Suppl. 2), 4-7 (2008).
49. Yanagawa, M. et al. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J. Nucl. Med. 53, 872-880 (2012).
50. Teng, F. F., Meng, X., Sun, X. D. & Yu, J. M. New strategy for monitoring targeted therapy: molecular imaging. Int. J. Nanomedicine 8, 3703-3713 (2013).
51. 18F]FDG-PET. Int. J. Radiat. Oncol. Biol. Phys. 82, 299-307 (2012).
52. 18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother. Oncol. 80, 151-156 (2006).
53. Ling, C. C. et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int. J. Radiat. Oncol. Biol. Phys. 47, 551-560 (2000).
54. 18fluoro-misonidazole (F-MISO) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother. Oncol. 98, 109-116 (2011).
55. 18F-FDG-PET/CT: Correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade. J. Magn. Reson. Imaging http://dx.doi.org/ 10.1002/jmri.24464.
56. 18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. J. Nucl. Med. 53, 1048-1057 (2012).
57. Buchbender, C., Heusner, T. A., Lauenstein, T. C., Bockisch, A. & Antoch, G. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J. Nucl. Med. 53, 928-938 (2012).
58. Buchbender, C., Heusner, T. A., Lauenstein, T. C., Bockisch, A. & Antoch, G. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J. Nucl. Med. 53, 1244-1252 (2012).
59. 18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur. J. Nucl. Med. Mol. Imaging 30, 695-704 (2003).
60. 18F-FDG PET. J. Nucl. Med. 47, 1921-1926 (2006).
61. Komar, G. et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin. Cancer Res. 15, 5511-5517 (2009).
62. Kamel, I. R. et al. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 250, 466-473 (2009).
63. Jenkinson, M. D. et al. Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma. J. Neurooncol. 99, 103-113 (2010).
64. Clarke, L. P. et al. The Quantitative Imaging Network: NCI's historical perspective and planned goals. Transl. Oncol. 7, 1-4 (2014).
65. QIBA Protocols and Profiles. Radiological Society of North America [online], http://www.rsna.org/ QIBA-Protocols-and-Profiles.aspx (2014).
66. ECOG-ACRIN cancer research group. ECOG-AGRIN.org [online], http://ecog-acrin.org/ about-us ( 2014).
67. Yankeelov, T. E. et al. Clinically relevant modeling of tumor growth and treatment response. Sci. Transl. Med. 5, 187ps9 (2013).
68. Szeto, M. D. et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res. 69, 4502-4509 (2009).
69. Atuegwu, N. C. et al. Parameterizing the logistic model of tumor growth by DW-MRI and DCE-MRI data to predict treatment response and changes in breast cancer cellularity during neoadjuvant chemotherapy. Transl. Oncol. 6, 256-264 (2013).
70. Hogea, C., Davatzikos, C. & Biros, G. An image-driven parameter estimation problem for a reaction-diffusion glioma growth model with mass effects. J. Math. Biol. 56, 793-825 (2008).
71. Yankeelov, T. E., Arlinghaus, L. R., Li, X. & Gore, J. C. The role of magnetic resonance imaging biomarkers in clinical trials of treatment response in cancer. Semin. Oncol. 38, 16-25 (2011).
72. Thakur, M. L. & Lentle, B. C. Report of a summit on molecular imaging. J. Nucl. Med. 46, 11N-42N (2005).
73. Jain, R. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
74. Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
75. Sorensen, A. G. et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 69, 5296-5300 (2009).
76. Sorensen, A. G. et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 72, 402-407 (2012).
77. Emblem, K. E. et al. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat. Med. 19, 1178-1183 (2013).
78. Ribatti, D. Vascular normalization: a real benefit? Cancer Chemother. Pharmacol. 68, 275-278 (2011).
79. 3 His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. J. Nucl. Med. 52, 1786-1794 (2011).